Baxter International Faces Class Action Over Novum LVP Product Safety Concerns
- Baxter International faces a class action lawsuit alleging securities fraud due to undisclosed defects in its Novum LVP product.
- The lawsuit claims malfunctions of the Novum LVP pose serious health risks and undermine patient safety and trust.
- Baxter may need to reassess quality control practices and restore trust amid ongoing legal and public relations challenges.
### Legal Action Highlights Concerns Over Baxter International's Novum LVP Product
Baxter International, Inc. faces a class action lawsuit filed by Levi & Korsinsky, LLP, which represents investors alleging securities fraud related to the company’s Novum Large Volume Pump (LVP). The lawsuit claims that between February 23, 2022, and July 30, 2025, Baxter failed to disclose systemic defects in the Novum LVP that led to significant malfunctions, including underinfusion and overinfusion of medication. These malfunctions pose serious health risks to patients, raising critical questions about the safety and reliability of Baxter’s medical devices. The complaint highlights that the company reportedly received numerous notifications regarding device failures and associated injuries, yet it allegedly did not take adequate measures to alert customers or rectify the issues.
The implications of the lawsuit extend beyond investor losses; they touch upon patient safety and trust in Baxter’s products. According to the allegations, Baxter’s failure to tackle these malfunctions could have severe consequences, including the potential removal of existing Novum LVPs from service and a halt in new sales. This situation could undermine Baxter’s position in the healthcare market, particularly in the infusion therapy segment, which is vital for patient care in hospitals and other medical settings. The complaint asserts that Baxter’s public statements regarding the safety and efficacy of the Novum LVPs were misleading, potentially inflating the company’s market prospects and investor confidence at the expense of transparency.
As Baxter navigates this legal challenge, the broader implications of the lawsuit may prompt the company to reassess its quality control and reporting practices. Maintaining the integrity of its medical devices is crucial for preserving both patient safety and shareholder value. The outcome of this case could set a precedent for how medical device manufacturers address product safety concerns, and it underscores the importance of transparent communication with both investors and healthcare providers. Investors affected by these developments have a deadline of December 15, 2025, to seek lead plaintiff status, although participation in the lawsuit does not require this and comes at no direct financial cost.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

